Cost-effectiveness of Screening Program for Chronic Q Fever, the Netherlands

• Main Authors: Pieter T. de Boer, Marit M.A. de Lange, Cornelia C.H. Wielders, Frederika Dijkstra, Sonja E. van Roeden, Chantal P. Bleeker-Rovers, Jan Jelrik Oosterheert, Peter M. Schneeberger, Wim van der Hoek
• Format: Article
• Language: English
• Published: Centers for Disease Control and Prevention 2020-02-01
• Series: Emerging Infectious Diseases
• Subjects: Q fever; Coxiella burnetii; cost-effectiveness; screening; economic evaluation; the Netherlands
• Online Access: https://wwwnc.cdc.gov/eid/article/26/2/18-1772_article
• ISSN: 1080-6040; 1080-6059

In the aftermath of a large Q fever (QF) epidemic in the Netherlands during 2007–2010, new chronic QF (CQF) patients continue to be detected. We developed a health-economic decision model to evaluate the cost-effectiveness of a 1-time screening program for CQF 7 years after the epidemic. The model was parameterized with spatial data on QF notifications for the Netherlands, prevalence data from targeted screening studies, and clinical data from the national QF database. The cost-effectiveness of screening varied substantially among subpopulations and geographic areas. Screening that focused on cardiovascular risk patients in areas with high QF incidence during the epidemic ranged from cost-saving to €31,373 per quality-adjusted life year gained, depending on the method to estimate the prevalence of CQF. The cost per quality-adjusted life year of mass screening of all older adults was €70,000 in the most optimistic scenario.